News|Articles|August 10, 2026

Novel mechanisms reshaping the phase 3 pipeline in wet and dry AMD

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

Currently, anti-VEGF therapy remains the backbone of wet age-related macular degeneration (AMD) treatment, and complement inhibition has defined the first approved therapies for geographic atrophy in dry AMD. Since their entrance to clinical practice, these medication classes have defined the standard for disease management; however, their impact has not resulted in a halting of seeking more innovative approaches to AMD.

Related to this article

November 2nd, 2026

FDA approves ranibizumab biosimilar Lucamzi for wet AMD

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

October 30th, 2026

Lambert-Eaton Myasthenic Syndrome: how eye care professionals differentiate it from myasthenia gravis

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.

October 26th, 2026

Women’s Health: Identifying dry eye in rheumatoid arthritis can make all the difference

Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.

October 22nd, 2026

Diabetic macular edema: an inflammatory disease in focus

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.